Nasus Pharma to Participate in Upcoming Investor Conferences Feb 20, 2026 08:00AM
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 Feb 17, 2026 08:00AM
Nasus Pharma completes $15 million private placement Feb 13, 2026 08:00AM
Nasus Pharma Announces Closing of $15.0 Million Private Placement Feb 13, 2026 08:00AM
Nasus Pharma prices $15 million private placement for drug development Feb 10, 2026 11:03PM


Feb 10, 2026 11:03PM Nasus Pharma Announces Pricing of $15.0 Million Private Placement
Jan 20, 2026 08:00AM Nasus Pharma reports faster epinephrine absorption in phase 2 trial
Jan 20, 2026 08:00AM Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Dec 22, 2025 08:00AM Nasus Pharma outlines 2026 clinical milestones for NS002 epinephrine
Dec 22, 2025 08:00AM Nasus Pharma CEO Issues 2025 Letter to Shareholders
Nov 20, 2025 08:15AM Nasus Pharma names Eyal Rubin as CFO and executive vice president
Nov 20, 2025 08:15AM Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer
Nov 18, 2025 08:00AM Nasus Pharma begins Phase 2 study of intranasal epinephrine treatment
Nov 18, 2025 08:00AM Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
Nov 6, 2025 08:00AM Nasus Pharma receives Health Canada approval to start NS002 phase 2 study
Nov 6, 2025 08:00AM Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Oct 8, 2025 08:04AM Nasus Pharma expands Aptar partnership for NS002 epinephrine development
Oct 8, 2025 08:04AM Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program